Artesunate + Ganciclovir for Cytomegalovirus

This trial tests a new combination of medicines to treat cytomegalovirus (CMV), a viral infection common in individuals who have undergone a solid organ transplant, such as a kidney, lung, heart, or liver. The study compares different doses of the drug artesunate (an antimalarial medication) combined with the standard antiviral treatment, ganciclovir, to determine the most effective option. Participants will receive either a high or low dose of artesunate with ganciclovir, or just the standard ganciclovir treatment. Candidates may be suitable if they have had a solid organ transplant and have a confirmed CMV infection requiring specific antiviral treatment. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people, providing an opportunity to contribute to significant medical advancements.

The trial requires participants to stop taking any anti-CMV antiviral drugs before joining. If you're on other medications, especially those that interact with artesunate or GCV, you might need to stop those too.

Previous studies have shown that artesunate is very safe. Most patients tolerated the low dose well, with no major safety issues. Some reported mild side effects, such as stomach cramps and diarrhea, particularly at higher doses. However, these side effects were not serious and could be managed.

For the high dose, similar mild side effects appeared. Importantly, the existing data reported no major safety concerns. Artesunate is also used to treat severe malaria and is generally well-tolerated in that context.

Researchers are excited about the investigational treatments involving artesunate and ganciclovir for cytomegalovirus (CMV) because they introduce artesunate, a new active ingredient with a different mechanism of action. Unlike the standard antiviral treatments like ganciclovir alone, which primarily inhibit viral replication, artesunate might enhance the immune response against the virus. With both high and low doses of artesunate being tested, there's potential to find a more effective combination that could work faster and possibly reduce side effects compared to current CMV treatments. This approach could offer a novel way to tackle CMV, especially for patients who don't respond well to existing therapies.

This trial will compare different treatment approaches for cytomegalovirus (CMV). Participants in one arm will receive high-dose Artesunate, which studies have shown can help stop CMV from multiplying. Specifically, in some patients, CMV levels did not increase after two weeks of high-dose treatment. Another arm will test low-dose Artesunate, where about 74% of patients had controlled CMV levels, and in 19% of cases, the virus was completely cleared. Artesunate is considered safe because it is already used to treat malaria, supporting its potential use for CMV. The trial will also include a standard treatment arm with Ganciclovir, a commonly used treatment for CMV.²⁴⁶⁷⁸